DRUG SPOTLIGHT Foundayo (orforglipron)

Manufacturer
Eli Lilly

FDA Approval Date:
4/1/2026

Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

Clinical Profile:
Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Foundayo is the 2nd oral GLP-1 approved for weight related indications after oral Wegovy, but the ability to take any time of day, with or without meals provides a convenience advantage.

Population:
It is estimated that approximately 40% of the US adult population is obese.

Pricing and Availability:
Tablets: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg of orforglipron. AWP of $779 for a 30 day supply. Self-pay (DTC) $149-$349 depending on dose.

Management Strategy:
Oral GLP-1 therapies are currently in active negotiation regarding formulary placement, and based on outcome they may be either preferred, non-preferred, or excluded. Clients must cover weight loss under the pharmacy benefit for claims to pay.

References
IPD Analytics

Additional Information Press Release Prescribing Information

Questions? Contact your ClearScript Clinical Account Executive